Elastyczność popytu na farmaceutyki typowego gospodarstwa domowego w krajach europejskich
DOI:
https://doi.org/10.18778/0208-6018.358.03Słowa kluczowe:
ekonomia zdrowia, bezpośrednie prywatne wydatki farmaceutyczne, dochodowa elastyczność popytu, cenowa elastyczność popytu, analizy regionalneAbstrakt
Według Światowej Organizacji Zdrowia (WHO) prawie miliard ludzi na całym świecie jest zagrożonych popadnięciem w ubóstwo z powodu wydatków na zdrowie, a farmaceutyki są integralną częścią rosnącego problemu. Niniejsze badanie ma na celu ocenę elastyczności cenowej i dochodowej popytu na leki w państwach europejskich w latach 2009–2019. Przedmiotem analizy jest typowe gospodarstwo domowe w każdym kraju. Analiza koncentruje się na ocenie problemu w świetle wzrostu gospodarczego. W związku z tym wyniki są porównywane według grup rozwoju krajów, aby wskazać wszelkie podobieństwa i różnice wewnątrz klastrów i między nimi. Wyniki wskazują, że gospodarstwa domowe w regionach biedniejszych są bardziej wrażliwe na bodźce ekonomiczne niż w krajach zamożnych. Zarówno elastyczność dochodowa, jak i cenowa wskazują na niezaspokojone zapotrzebowanie na leki z powodu niewystarczających zasobów finansowych. Co więcej, reakcja gospodarstw domowych na zmiany dochodów i cen różni się w zależności od czasu, kraju i klastrów.
Pobrania
Bibliografia
Alghanim S.A. (2011), Self-medication practice among patients in a public health care system, “Eastern Mediterranean Health Journal”, vol. 17, no. 5, pp. 409–416. DOI: https://doi.org/10.26719/2011.17.5.409
Ben-Aharon O., Shavit O., Magnezi R. (2017), Does drug price-regulation affect healthcare expenditures?, “The European Journal of Health Economics”, vol. 18, pp. 859–867, https://doi.org/10.1007/s10198-016-0832-z DOI: https://doi.org/10.1007/s10198-016-0832-z
Besanko D., Braeutigam R. (2013), Microeconomics, John Wiley & Sons, Hoboken.
Bhattacharya J., Hyde T., Tu P. (2013), Health Economics, Macmillan International Higher Education, New York. DOI: https://doi.org/10.1007/978-1-137-02997-3
Colorectal cancer burden in EU–27 (2021), European Cancer Information System, European Union, https://ecis.jrc.ec.europa.eu/pdf/Colorectal_cancer_factsheet-Mar_2021.pdf (accessed: 1.08.2021).
Du J., Yang X., Chen M., Wang Z. (2019), Socioeconomic determinants of out-of-pocket pharmaceutical expenditure among middle-aged and elderly adults based on the China Health and Retirement Longitudinal Survey, “BMJ Open”, vol. 9, pp. 1–13, https://doi.org/10.1136/bmjopen-2018-024936 DOI: https://doi.org/10.1136/bmjopen-2018-024936
Dunphy C., Peterson C., Zhang K., Jones C.M. (2021), Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?, “Drug and Alcohol Dependence”, vol. 225, pp. 1–5, https://doi.org/10.1016/j.drugalcdep.2021.108784 DOI: https://doi.org/10.1016/j.drugalcdep.2021.108784
Dwivedi D.N. (2002), Microeconomics: Theory And Applications, Pearson Education India, Delhi.
Eurostat (n.d.), Harmonised Indices of Consumer Prices (HICP) – FAQ, https://ec.europa.eu/eurostat/web/hicp/faq (accessed: 13.08.2021).
Eurostat (n.d.), Health care expenditure, https://ec.europa.eu/eurostat/cache/metadata/en/hlth_sha11_esms.htm (accessed: 13.08.2021).
Eurostat Database (n.d.), https://ec.europa.eu/eurostat/data/database (accessed: 1.08.2021). DOI: https://doi.org/10.1007/978-3-319-69909-7_944-2
Gazaway S.B., Barnett M.D., Bowman E.H., Ejem D., Harrell E.R., Brown C.J., Bakitas M. (2021), Health Professionals Palliative Care Education for Older Adults: Overcoming Ageism, Racism, and Gender Bias, “Current Geriatrics Reports”, no. 10, pp. 148–156, https://doi.org/10.1007/s13670-021-00365-7 DOI: https://doi.org/10.1007/s13670-021-00365-7
Glied S., Smith P.C. (2013), The Oxford Handbook of Health Economics, Oxford University Press, Oxford.
Guinness L., Wiseman V . (2011), Introduction To Health Economics, McGraw-Hill Education, Berkshire.
MacDonald M. (1995), Feminist economics: from theory to research, “Canadian Journal of Economics”, vol. 28, no. 1, pp. 159–176. DOI: https://doi.org/10.2307/136027
Makowska M., Boguszewski R., Nowakowski M., Podkowińska M. (2020), Self-Medication-Related Behaviors and Poland’s COVID–19 Lockdown, “International Journal of Environmental Research and Public Health”, vol. 17, no. 8344, https://doi.org/10.3390/ijerph17228344 DOI: https://doi.org/10.3390/ijerph17228344
Matin B.K., Azami S.R., Mahmoudi S., Rezaei S., Shaahmadi F., Karyani A.K. (2015), Determinants of pharmaceutical expenditures of urban households: A time series study in Kermanshah province (Iran), “Electron Physician”, vol. 7, no. 7, https://doi.org/10.19082/1470 DOI: https://doi.org/10.19082/1470
McClellan C., Fingar K.R., Ali M.M., Olesiuk W.J., Mutterd R., Gibson T.B. (2019), Price elasticity of demand for buprenorphine/naloxone prescriptions, “Journal of Substance Abuse Treatment”, vol. 106, pp. 4–11, https://doi.org/10.1016/j.jsat.2019.08.001 DOI: https://doi.org/10.1016/j.jsat.2019.08.001
Murphy S.M., Morgan J.R., Jeng P.J., Schackman B.R. (2019), Will converting naloxone to over-the-counter status increase pharmacy sales?, “Health Services Research”, vol. 54, issue 4, pp. 764–772, https://doi.org/10.1111/1475-6773.13125 DOI: https://doi.org/10.1111/1475-6773.13125
O’Brien G.L., McAlister M., Byrne S., Gallagher J. (2020a), Overcoming hurdles: measurement of health-related outcomes associated with national level medicines usage in Ireland, “Drugs in Context”, vol. 9, no. 4–2, https://doi.org/10.7573/dic.2020-4-2 DOI: https://doi.org/10.7573/dic.2020-4-2
O’Brien G.L., Sinnott S.-J., O’Flynn B., Walshe V., Mulcahy M., Byrne S. (2020b), Out of pocket or out of control: A qualitative analysis of healthcare professional stakeholder involvement in pharmaceutical policy change in Ireland, “Health Policy”, vol. 124, issue 4, pp. 411–418, https://doi.org/10.1016/j.healthpol.2020.02.011 DOI: https://doi.org/10.1016/j.healthpol.2020.02.011
OECD (2003), Glossary of statistical terms, https://stats.oecd.org/glossary/ (accessed: 12.08.2021).
Olsen J.A. (2017), Principles in Health Economics and Policy, Oxford University Press, Oxford. DOI: https://doi.org/10.1093/oso/9780198794837.001.0001
Santerre R.E., Vemont J.A. (2006), Assessing Consumer Gains from a Drug Price Control Policy in the United States, “Southern Economic Journal”, vol. 73(1), pp. 233–245. DOI: https://doi.org/10.1002/j.2325-8012.2006.tb00768.x
Sanwald A., Theurl E. (2017), Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey, “European Journal of Health Economics”, vol. 18, pp. 435–447, https://doi.org/10.1007/s10198-016-0797-y DOI: https://doi.org/10.1007/s10198-016-0797-y
Siminski P. (2011), The price elasticity of demand for pharmaceuticals amongst high income older Australians: a natural experiment, “Applied Economics”, vol. 43, pp. 4835–4846. DOI: https://doi.org/10.1080/00036846.2010.498361
Sloan F.A., Hsieh C.-R. (2017), Health Economics, MIT Press, Cambridge.
WHO (n.d.), Essential medicines, http://www.emro.who.int/health-topics/essential-medicines/index.html (accessed: 16.08.2021).
WHO (n.d.), European Region Health Expenditure Dashboard, https://www.who.int/health_financing/topics/resource-tracking/European-Region-Health-Expenditure-Dashboard.pdf (accessed: 16.08.2021).
WHO (n.d.), Global Essential Medicines, https://global.essentialmeds.org/dashboard/countries/97 (accessed: 16.08.2021).
WHO (n.d.), Global Health Expenditure Database, https://apps.who.int/nha/database/Home/Index/en (accessed: 16.08.2021).
WHO (n.d.), Global Health Expenditure Database. Health Expenditure Profile, https://apps.who.int/nha/database/country_profile/Index/en (accessed: 16.08.2021).
WHO (n.d.), Health accounts, https://www.who.int/health-topics/health-accounts#tab=tab_1 (accessed: 16.08.2021).
WHO (n.d.), Health budget, https://www.who.int/health-topics/health-budget#tab=tab_1 (accessed: 16.08.2021).
WHO (n.d.), Pharmaceutical products, http://www.emro.who.int/health-topics/pharmaceutical-products/index.html (accessed: 16.08.2021).
WHO (2000a), Guidelines for the regulatory assessment of medicinal products for use in self-medication, https://apps.who.int/iris/handle/10665/66154 (accessed: 16.08.2021).
WHO (2000b), WHO report on cancer: setting priorities, investing wisely and providing care for all, Geneva.
WHO (2001), WHO/WTO Workshop on Pricing and Financing of Essential Drugs, https://www.who.int/news/item/11-04-2001-who-wto-workshop-on-pricing-and-financing-of-essential-drugs (accessed: 25.08.2021).
WHO (2013), Prequalification of medicines by WHO, https://www.who.int/news-room/fact-sheets/detail/prequalification-of-medicines-by-who (accessed: 16.08.2021).
WHO (2018), WHO Report: Medicines reimbursement policies in Europe, Geneva.
WHO (2019), WHO Report: Global spending on health: a world in transition, “WHO/HIS/HGF/HFWorkingPaper”, no. 19.4.
WHO (2020), WHO Report: Global spending on health 2020: weathering the storm, Geneva.
WHO (2021a), Cardiovascular diseases (CVDs), https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed: 30.07.2021).
WHO (2021b), Primary health care, https://www.who.int/news-room/fact-sheets/detail/primary-health-care (accessed: 16.08.2021).
Xu K., Soucat A., Kutzin J., Brindley C., Maele N. van de, Touré H., Aranguren Garcia M., Li D., Barroy H., Flores G., Roubal T., Indikadahena C., Cherilova V., Siroka A. (2018), Public Spending on Health: A Closer Look at Global Trends, ”WHO/HIS/HGF/HF Working Paper”, no. 18.3, World Health Organization, Geneva.
Pobrania
Opublikowane
Numer
Dział
Jak cytować
